Two months after the FDA issued a safety alert on Pfizer's Chantix, the company in January agreed to update labeling to warn patients about the potential for serious neuropsychiatric symptoms.
It's still entirely up to drugmakers whether they want to make their products available on an experimental basis. Patients may not see it that way.
Two FDA guidance documents aim to help pharma companies show the value of their drugs to payers beyond what's included in FDA labeling.
For the first time, the nonprofit is trying to eliminate bans on gay and bisexual men donating blood in countries other than the U.S.
